Gilead (GILD) Q4 FY24 earnings call

Gilead delivered strong Q4 and full-year results, driven by robust demand in HIV, oncology, and liver disease, exceeding revenue guidance. The company is advancing a diverse pipeline, particularly in HIV prevention with lenacapavir and oncology with Trodelvy and cell therapies, while navigating near-term headwinds from Medicare Part D reform and FX. Management aims to maintain expense discipline and leverage its model for continued bottom-line growth.